 |
PDBsum entry 2v5x
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of hdac8-inhibitor complex
|
|
Structure:
|
 |
Histone deacetylase 8. Chain: a, b. Synonym: hdac8, hd8. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Resolution:
|
 |
|
2.25Å
|
R-factor:
|
0.198
|
R-free:
|
0.240
|
|
|
Authors:
|
 |
S.Di Marco,A.Vannini,C.Volpari,P.Gallinari,P.Jones,M.Mattu,A.Carfi, R.Defrancesco,C.Steinkuhler
|
Key ref:
|
 |
A.Vannini
et al.
(2007).
Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex.
EMBO Rep,
8,
879-884.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
10-Jul-07
|
Release date:
|
04-Sep-07
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
Q9BY41
(HDAC8_HUMAN) -
Histone deacetylase 8 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
377 a.a.
363 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 1 residue position (black
cross)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
E.C.3.5.1.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.3.5.1.98
- histone deacetylase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
N6-acetyl-L-lysyl-[histone] + H2O = L-lysyl-[histone] + acetate
|
 |
 |
 |
 |
 |
N(6)-acetyl-L-lysyl-[histone]
|
+
|
H2O
|
=
|
L-lysyl-[histone]
|
+
|
acetate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
EMBO Rep
8:879-884
(2007)
|
|
PubMed id:
|
|
|
|
|
| |
|
Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex.
|
|
A.Vannini,
C.Volpari,
P.Gallinari,
P.Jones,
M.Mattu,
A.Carfí,
R.De Francesco,
C.Steinkühler,
S.Di Marco.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Histone deacetylases (HDACs)-an enzyme family that deacetylates histones and
non-histone proteins-are implicated in human diseases such as cancer, and the
first-generation of HDAC inhibitors are now in clinical trials. Here, we report
the 2.0 A resolution crystal structure of a catalytically inactive HDAC8
active-site mutant, Tyr306Phe, bound to an acetylated peptidic substrate. The
structure clarifies the role of active-site residues in the deacetylation
reaction and substrate recognition. Notably, the structure shows the unexpected
role of a conserved residue at the active-site rim, Asp 101, in positioning the
substrate by directly interacting with the peptidic backbone and imposing a
constrained cis-conformation. A similar interaction is observed in a new
hydroxamate inhibitor-HDAC8 structure that we also solved. The crucial role of
Asp 101 in substrate and inhibitor recognition was confirmed by activity and
binding assays of wild-type HDAC8 and Asp101Ala, Tyr306Phe and
Asp101Ala/Tyr306Phe mutants.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1 Structure of the human HDAC8–substrate complex. (A)
Ribbon diagram of the two HDAC8–substrate complexes in the
asymmetric unit. The substrate and residues involved in the
head-to-head packing are shown in a stick representation.
Carbon, oxygen and nitrogen for the substrate are green, red
and blue, respectively. Zn^2+ and K^+ ions are represented as
purple spheres. (B) Enlarged view of the substrate-binding site
in the asymmetric unit with the 1.0 -contoured
2F[o]-F[c] electron density map. (C) HDAC8 monomer with the
bound substrate. Atoms are coloured as in (A). (D) Enlarged view
of the active site. Polar interactions are shown as dashed
yellow lines. HDAC, histone deacetylase.
|
 |
Figure 3.
Figure 3 Comparison of the structure of HDAC8–substrate with
that of the HDAC8–hydroxamate inhibitor. (A) View of the
substrate-binding site superimposed with the structure of the
HDAC8–inhibitor (r.m.s.d.-C ,
0.315 Å). Oxygen, nitrogen and carbon of the inhibitor are
red, blue and cyan, respectively. Protein is cyan in the
HDAC8–inhibitor structure. (B) Molecular surface of the
HDAC8–substrate complex at the active-site entrance. Water
molecules are shown as red spheres. (C) Molecular surface of the
HDAC8–inhibitor complex. HDAC, histone deacetylase.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
EMBO Rep
(2007,
8,
879-884)
copyright 2007.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.A.Deardorff,
M.Bando,
R.Nakato,
E.Watrin,
T.Itoh,
M.Minamino,
K.Saitoh,
M.Komata,
Y.Katou,
D.Clark,
K.E.Cole,
E.De Baere,
C.Decroos,
N.Di Donato,
S.Ernst,
L.J.Francey,
Y.Gyftodimou,
K.Hirashima,
M.Hullings,
Y.Ishikawa,
C.Jaulin,
M.Kaur,
T.Kiyono,
P.M.Lombardi,
L.Magnaghi-Jaulin,
G.R.Mortier,
N.Nozaki,
M.B.Petersen,
H.Seimiya,
V.M.Siu,
Y.Suzuki,
K.Takagaki,
J.J.Wilde,
P.J.Willems,
C.Prigent,
G.Gillessen-Kaesbach,
D.W.Christianson,
F.J.Kaiser,
L.G.Jackson,
T.Hirota,
I.D.Krantz,
and
K.Shirahige
(2012).
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle.
|
| |
Nature,
489,
313-317.
|
 |
|
|
|
|
 |
A.Linares,
F.Dalenc,
P.Balaguer,
N.Boulle,
and
V.Cavailles
(2011).
Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?
|
| |
J Biomed Biotechnol,
2011,
856985.
|
 |
|
|
|
|
 |
F.Lonardo,
X.Li,
A.Kaplun,
A.Soubani,
S.Sethi,
S.Gadgeel,
and
S.Sheng
(2010).
The natural tumor suppressor protein maspin and potential application in non small cell lung cancer.
|
| |
Curr Pharm Des,
16,
1877-1881.
|
 |
|
|
|
|
 |
R.H.Wilting,
E.Yanover,
M.R.Heideman,
H.Jacobs,
J.Horner,
J.van der Torre,
R.A.DePinho,
and
J.H.Dannenberg
(2010).
Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis.
|
| |
EMBO J,
29,
2586-2597.
|
 |
|
|
|
|
 |
S.L.Gantt,
C.G.Joseph,
and
C.A.Fierke
(2010).
Activation and inhibition of histone deacetylase 8 by monovalent cations.
|
| |
J Biol Chem,
285,
6036-6043.
|
 |
|
|
|
|
 |
A.Bougdour,
D.Maubon,
P.Baldacci,
P.Ortet,
O.Bastien,
A.Bouillon,
J.C.Barale,
H.Pelloux,
R.Ménard,
and
M.A.Hakimi
(2009).
Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites.
|
| |
J Exp Med,
206,
953-966.
|
 |
|
|
|
|
 |
B.C.Smith,
and
J.M.Denu
(2009).
Chemical mechanisms of histone lysine and arginine modifications.
|
| |
Biochim Biophys Acta,
1789,
45-57.
|
 |
|
|
|
|
 |
B.He,
S.Velaparthi,
G.Pieffet,
C.Pennington,
A.Mahesh,
D.L.Holzle,
M.Brunsteiner,
R.van Breemen,
S.Y.Blond,
and
P.A.Petukhov
(2009).
Binding ensemble profiling with photoaffinity labeling (BEProFL) approach: mapping the binding poses of HDAC8 inhibitors.
|
| |
J Med Chem,
52,
7003-7013.
|
 |
|
|
|
|
 |
D.Wang
(2009).
Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors.
|
| |
Curr Top Med Chem,
9,
241-256.
|
 |
|
|
|
|
 |
P.Galletti,
A.Quintavalla,
C.Ventrici,
G.Giannini,
W.Cabri,
S.Penco,
G.Gallo,
S.Vincenti,
and
D.Giacomini
(2009).
Azetidinones as Zinc-Binding Groups to Design Selective HDAC8 Inhibitors.
|
| |
ChemMedChem,
4,
1991-2001.
|
 |
|
|
|
|
 |
R.Wu,
P.Hu,
S.Wang,
Z.Cao,
and
Y.Zhang
(2009).
Flexibility of Catalytic Zinc Coordination in Thermolysin and HDAC8: A Born-Oppenheimer ab initio QM/MM Molecular Dynamics Study.
|
| |
J Chem Theory Comput,
6,
337.
|
 |
|
|
|
|
 |
Y.Luo,
W.Jian,
D.Stavreva,
X.Fu,
G.Hager,
J.Bungert,
S.Huang,
and
Y.Qiu
(2009).
Trans-regulation of histone deacetylase activities through acetylation.
|
| |
J Biol Chem,
284,
34901-34910.
|
 |
|
|
|
|
 |
A.J.Vegas,
J.H.Fuller,
and
A.N.Koehler
(2008).
Small-molecule microarrays as tools in ligand discovery.
|
| |
Chem Soc Rev,
37,
1385-1394.
|
 |
|
|
|
|
 |
A.Schuetz,
J.Min,
A.Allali-Hassani,
M.Schapira,
M.Shuen,
P.Loppnau,
R.Mazitschek,
N.P.Kwiatkowski,
T.A.Lewis,
R.L.Maglathin,
T.H.McLean,
A.Bochkarev,
A.N.Plotnikov,
M.Vedadi,
and
C.H.Arrowsmith
(2008).
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity.
|
| |
J Biol Chem,
283,
11355-11363.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.P.Dowling,
L.Di Costanzo,
H.A.Gennadios,
and
D.W.Christianson
(2008).
Evolution of the arginase fold and functional diversity.
|
| |
Cell Mol Life Sci,
65,
2039-2055.
|
 |
|
|
|
|
 |
D.P.Dowling,
S.L.Gantt,
S.G.Gattis,
C.A.Fierke,
and
D.W.Christianson
(2008).
Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors.
|
| |
Biochemistry,
47,
13554-13563.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.J.Bottomley,
P.Lo Surdo,
P.Di Giovine,
A.Cirillo,
R.Scarpelli,
F.Ferrigno,
P.Jones,
P.Neddermann,
R.De Francesco,
C.Steinkühler,
P.Gallinari,
and
A.Carfí
(2008).
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain.
|
| |
J Biol Chem,
283,
26694-26704.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Z.A.Gurard-Levin,
and
M.Mrksich
(2008).
The activity of HDAC8 depends on local and distal sequences of its peptide substrates.
|
| |
Biochemistry,
47,
6242-6250.
|
 |
|
|
|
|
 |
S.Lall
(2007).
Primers on chromatin.
|
| |
Nat Struct Mol Biol,
14,
1110-1115.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |